Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.

Viking Therapeutics (VKTX) is back in the spotlight with investors eyeing the company’s advancing clinical pipeline, including its VK2735 obesity drug now in phase 3 trials. Expectations are also ...

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Explore the exciting world of Viking Holdings (NYSE: VIK) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...

Viking is not your typical cruise operator. Stream NBC 5 for free, 24/7, wherever you are. Aboard its smaller, upscale vessels, you won't find any kids. In fact, the cruise line doesn't hide the fact ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...